Ameriprise Financial Inc. grew its position in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) by 42.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 966,995 shares of the biopharmaceutical company’s stock after purchasing an additional 286,545 shares during the quarter. Ameriprise Financial Inc. owned about 2.61% of OncoMed Pharmaceuticals worth $3,221,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of OncoMed Pharmaceuticals by 5.1% in the first quarter. Vanguard Group Inc. now owns 945,485 shares of the biopharmaceutical company’s stock valued at $8,708,000 after purchasing an additional 45,494 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of OncoMed Pharmaceuticals by 13.7% in the first quarter. Renaissance Technologies LLC now owns 533,600 shares of the biopharmaceutical company’s stock valued at $4,914,000 after purchasing an additional 64,300 shares during the last quarter. Cannell Peter B & Co. Inc. grew its position in shares of OncoMed Pharmaceuticals by 23.1% in the second quarter. Cannell Peter B & Co. Inc. now owns 407,741 shares of the biopharmaceutical company’s stock valued at $1,358,000 after purchasing an additional 76,445 shares during the last quarter. First Eagle Investment Management LLC grew its position in shares of OncoMed Pharmaceuticals by 37.6% in the second quarter. First Eagle Investment Management LLC now owns 219,420 shares of the biopharmaceutical company’s stock valued at $731,000 after purchasing an additional 60,000 shares during the last quarter. Finally, Marshall Wace North America L.P. acquired a new position in shares of OncoMed Pharmaceuticals in the second quarter valued at approximately $561,000. 51.70% of the stock is currently owned by institutional investors.

Several equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $6.00 target price on shares of OncoMed Pharmaceuticals in a research report on Tuesday, September 19th. Jefferies Group LLC reissued a “buy” rating and set a $5.00 price target on shares of OncoMed Pharmaceuticals in a research report on Thursday, September 28th. SunTrust Banks, Inc. reissued a “hold” rating and set a $4.00 price target on shares of OncoMed Pharmaceuticals in a research report on Friday, October 6th. Zacks Investment Research raised OncoMed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Wednesday, October 4th. Finally, Piper Jaffray Companies set a $5.00 price target on OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $5.84.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/29/ameriprise-financial-inc-boosts-stake-in-oncomed-pharmaceuticals-inc-omed.html.

Shares of OncoMed Pharmaceuticals, Inc. (OMED) opened at 3.76 on Friday. OncoMed Pharmaceuticals, Inc. has a 12 month low of $2.91 and a 12 month high of $10.89. The company’s 50-day moving average price is $4.28 and its 200-day moving average price is $3.91. The firm’s market cap is $141.49 million.

OncoMed Pharmaceuticals (NASDAQ:OMED) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. The business had revenue of $6.20 million during the quarter, compared to analysts’ expectations of $6.08 million. During the same quarter in the prior year, the firm posted ($0.91) earnings per share. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. On average, analysts predict that OncoMed Pharmaceuticals, Inc. will post ($1.85) EPS for the current year.

OncoMed Pharmaceuticals Profile

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Institutional Ownership by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)

Receive News & Stock Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.